N-Methyl-D-aspartate antagonists and neuropathic pain:: The search for relief

[1] The competitive N-methyl-D-aspartate receptor antagonist (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959) potentiates the antinociceptive effects of opioids that vary in efficacy at the μ-opioid receptor [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 307 (02) : 785 - 792

[2] Angusti Angela, 2005, Farmaco (Lausanne), V60, P393, DOI 10.1016/j.farmac.2005.03.007

[3] Chronic morphine treatment alters expression of N-methyl-D-aspartate receptor subunits in the extended amygdala [J]. JOURNAL OF NEUROSCIENCE RESEARCH, 2006, 83 (04) : 532 - 537

[4] BAUDY RB, 2005, 230 NAT M AM CHEM SO

[5] BORSOOK D, 2003, CUR OPIN INVEST DRUG, V3, P1342

[6] Effects of the N-methyl-D-aspartate receptor antagonist perzinfotel [EAA-090; [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl] phosphonic acid] on chemically induced thermal hypersensitivity [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 313 (03) : 1379 - 1386

[7] N-methyl-D-aspartate receptor (NMDA) antagonists as potential pain therapeutics [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (08) : 749 - 770

[8] Carlton S M, 2001, Curr Opin Pharmacol, V1, P52, DOI 10.1016/S1471-4892(01)00002-9

[9] EAA-090 - Neuroprotectant, Competitive NMDA antagonist [J]. DRUGS OF THE FUTURE, 2002, 27 (07) : 633 - 638

[10] NMDA antagonists and neuropathic pain - Multiple drug targets and multiple uses [J]. CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (23) : 2977 - 2994

[1] The competitive N-methyl-D-aspartate receptor antagonist (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959) potentiates the antinociceptive effects of opioids that vary in efficacy at the μ-opioid receptor [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 307 (02) : 785 - 792

[2] Angusti Angela, 2005, Farmaco (Lausanne), V60, P393, DOI 10.1016/j.farmac.2005.03.007

[3] Chronic morphine treatment alters expression of N-methyl-D-aspartate receptor subunits in the extended amygdala [J]. JOURNAL OF NEUROSCIENCE RESEARCH, 2006, 83 (04) : 532 - 537

[4] BAUDY RB, 2005, 230 NAT M AM CHEM SO

[5] BORSOOK D, 2003, CUR OPIN INVEST DRUG, V3, P1342

[6] Effects of the N-methyl-D-aspartate receptor antagonist perzinfotel [EAA-090; [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl] phosphonic acid] on chemically induced thermal hypersensitivity [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 313 (03) : 1379 - 1386

[7] N-methyl-D-aspartate receptor (NMDA) antagonists as potential pain therapeutics [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (08) : 749 - 770

[8] Carlton S M, 2001, Curr Opin Pharmacol, V1, P52, DOI 10.1016/S1471-4892(01)00002-9

[9] EAA-090 - Neuroprotectant, Competitive NMDA antagonist [J]. DRUGS OF THE FUTURE, 2002, 27 (07) : 633 - 638

[10] NMDA antagonists and neuropathic pain - Multiple drug targets and multiple uses [J]. CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (23) : 2977 - 2994